Please assess the completion status of the following clinical trial:

Trial Title: An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult participants of both genders who are 18 years or older~* Diagnosis of RA for at least 6 months according to the criteria of the American College of Rheumatology (ACR) of 1987 for the RA classification~* Participants with medically prescribed or being administered with unique rituximab infusion in the least 3 days, according to the approved label~* Ability to meet the program's requirements and to voluntarily sign the Informed Consent Term.~Exclusion Criteria:~* Participants who have received any investigational medication within less than or equal to (\<=) 1 year before the first dose of the currently indicated treatment~* Participants with an active infection~* Participants with conditions that may interfere in the ability to understand the requests of data collection and to obey to the study's requirements~* Functional Class IV defined based on the ACR functionality criteria for RA~* Participants who can not or who do not want, for any reason, to answer the questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: None): Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.

Based on this trial design, predict the completion outcome and termination type (if applicable).